|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Loss of heterozygosity of chromosome 10 and mutations in the tumor suppressor gene PTEN on 10q are molecular hallmarks of glioblastomas.
|
15924253 |
2005 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PTEN, which is frequently mutated in glioblastomas, is a tumor suppressor gene that encodes a dual specificity phosphatase that antagonizes the phosphatidylinositol 3-kinase class I/AKT/mTOR pathway, which is a key regulator of autophagy.
|
24349488 |
2013 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTEN/MMAC1 (phosphatase and tensin homolog/mutated in multiple advanced cancers 1) is a tumor suppressor gene, the inactivation of which is an important step in the progression of gliomas to end-stage glioblastoma multiforme.
|
11303623 |
2000 |
|
Glioblastoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
|
18566746 |
2008 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Cell surface area and membrane folding in glioblastoma cell lines differing in PTEN and p53 status.
|
24498019 |
2014 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we show that some PTEN-deficient GBM tumors produce a series of CD133(+) and CD133(-) self-renewing tumor-initiating cell types and provide evidence that these cell types constitute a lineage hierarchy.
|
20385361 |
2010 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The data presented here confirm that dacomitinib clearly affects receptor signaling in vivo and that its strong antitumoral effect is independent of the presence of mutant receptor isoforms although it could be affected by the PTEN status (as it is less effective in a PTEN-deleted GBM line).
|
25939761 |
2015 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In preliminary screens, mutations of PTEN were detected in 31% (13/42) of glioblastoma cell lines and xenografts, 100% (4/4) of prostate cancer cell lines, 6% (4/65) of breast cancer cell lines and xenografts, and 17% (3/18) of primary glioblastomas.
|
9072974 |
1997 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Glioblastoma harbors frequent alterations in receptor tyrosine kinases, phosphatidylinositol‑3 kinase (PI3K) and phosphatase and tensin homolog (PTEN) that dysregulate phospholipid signaling driven tumor proliferation and therapeutic resistance.
|
30942445 |
2019 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Correction of PTEN mutations in glioblastoma cell lines via AAV-mediated gene editing.
|
28464039 |
2017 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The psiPTEN expression was complementary to PTEN mutation, for 14 of 18 glioblastomas showed either PTEN mutation or psiPTEN expression and only one case showed both PTEN mutation and psiPTEN expression (P<0.046), suggesting a pathological role of psiPTEN expression as an alternative to PTEN mutation in glioblastomas.
|
10980610 |
2000 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutation of PTEN, amplification of EGFR, and loss of the q arm of chromosome 10 were statistically significantly less common in anaplastic astrocytoma than in glioblastoma multiforme (P =.033, P =.001, and P<.001, respectively), and mutation of p53 was statistically significantly more common (P<.001).
|
11504770 |
2001 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Most recently, a putative tumor suppressor gene (PTEN/MMAC1) has been identified in the region between D10S215 and an adjacent, more telomeric marker (D10S541) and was found to be altered in breast cancers, prostate cancers, and glioblastomas.
|
9491329 |
1998 |
|
Glioblastoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that PTEN expression potently suppressed the growth and tumorigenicity of human glioblastoma U87MG cells.
|
9860981 |
1998 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We also identified protein signatures for GBMs with genetic alterations (IDH mutation, p53 mutation, EGFR amplification or mutation, CDKN2A/CDKN2B deletion, and PTEN mutation) that occur at high frequency.
|
30401645 |
2019 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
WITHDRAWAL: Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the Glioblastoma (GBM) patients in the backdrop of mutational status of EGFR and PTEN genes.
|
29444555 |
2018 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The effect of miR-579 on the PI3K/AKT pathway in human glioblastoma PTEN mutant cell lines.
|
31243804 |
2019 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
It demonstrated that the incidence of PTEN mutations was 8/22 in these patients: one patient with WHO grade III glioma (1/11) and 7 patients with WHO grade IV glioma (7/11).
|
20393024 |
2010 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Interestingly, amplification of Epidermal growth factor receptor (EGFR) in the background of heterozygous PTEN knockout mice develop invasive glioma very similar to human glioblastoma, demonstrating the importance of PTEN in glioma progression and providing a model system to evaluate the efficacy of targeting PTEN in glioblastoma.
|
18836294 |
2008 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our data indicate that inhibition of ILK signaling may be beneficial in the treatment of PTEN-deficient glioblastoma.
|
15105053 |
2004 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Although deletions or inactivating mutations of the tumor suppressor gene PTEN (phosphatase and tensin homolog deleted on chromosome 10) are involved in the development of a variety of tumors including glioblastoma, melanoma, prostate cancer, breast cancer, endometrial cancers etc., the role of PTEN expression in human primary hepatocellular carcinoma (HCC) has not yet been clarified.
|
12669234 |
2003 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Phosphatase and tensin homolog located on chromosome 10 (PTEN) is one of the most frequently mutated tumor suppressors in human cancer including in glioblastoma.
|
23908595 |
2013 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
LHGDN |
PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors.
|
17255257 |
2007 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas; the involvement of tumor suppressor genes, other than PTEN, has been suggested.
|
10653004 |
2000 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The final progression process leading to glioblastoma multiforme seems to need additional genetic abnormalities in the long arm of chromosome 10; one of which is deletion and/or functional loss of the PTEN/MMAC1 gene.
|
11550308 |
1999 |